Table 1.
Characteristics of pregnant women at enrollment
| Characteristic | Efavirenz (N = 195) | Lopinavir/ritonavir (N = 194) |
|---|---|---|
| Maternal age, years, mean (SD) | 29.5 (5.4) | 29.0 (5.4) |
| Gestational age, weeks, median (IQR) | 21.3 (17.9, 24.4) | 21.2 (17.6, 25.0) |
| Education level, n (%) | ||
| None | 24 (12.3) | 24 (12.4) |
| Primary | 125 (64.1) | 135 (70.0) |
| More than primary | 46 (23.6) | 34 (17.6) |
| Number of previous pregnancies, n (%) | ||
| None | 16 (8.2) | 8 (4.1) |
| 1–2 | 50 (25.6) | 53 (27.3) |
| 3 or more | 129 (66.2) | 133 (68.6) |
| Number of living children, n (%) | ||
| None | 22 (11.3) | 16 (8.3) |
| 1–2 | 65 (33.3) | 67 (34.5) |
| 3 or more | 108 (55.4) | 111 (57.2) |
| HIV diagnosed in current pregnancy, n (%) | 87 (44.6) | 73 (37.6) |
| Body mass index, kg/m2, mean (SD) | 21.8 (3.1) | 22.1 (2.9) |
| Hemoglobin, g/dl, mean (SD) | 10.9 (1.3) | 11.0 (1.2) |
| CD4 cell count, cells/mm3, median (IQR) | 374 (270, 485) | 368 (282, 506) |
| HIV-1 RNA, log10 copies/ml, median (IQR) | 4.3 (3.5, 4.8) | 4.1 (3.3, 4.7) |
| WHO stage, n (%) | ||
| 1 | 181 (92.8) | 189 (97.4) |
| 2 | 13 (6.7) | 5 (2.6) |
| 3 | 1 (0.5) | 0 (0.0) |
| On TS prophylaxis prior to enrollment, n (%) | 125 (64.1) | 124 (63.9) |
NOTE. TS, trimethoprim-sulfamethoxazole